Thymosin beta-4 and Alzheimer’s: two studies, and what they mean for TB-500

Thymosin beta-4 (Tβ4) is a small protein made throughout the body, best known for its role in wound healing and tissue repair. A synthetic fragment of it is widely sold as “TB-500.” Over the past few years, Tβ4 has also turned up in Alzheimer’s disease research. Two studies in particular are worth understanding, including what they do and don’t say about TB-500.

Study 1: Tβ4 calmed brain inflammation in Alzheimer’s mice (2021)

Published in the Journal of Neuroinflammation, this study used APP/PS1 mice, a standard model that develops amyloid plaques and memory problems in middle age. The researchers started treatment at eight months, once disease was well established, and followed the mice for about five more months.

How Tβ4 was delivered matters. The mice didn’t get injections of the peptide. Instead, the team used a gene-therapy virus injected directly into the hippocampus and cortex, so brain cells would produce extra Tβ4 themselves.

What they found:

Brain immune cells shifted to a calmer state. Microglia and astrocytes moved away from an inflammatory profile toward a protective one. Inflammatory markers fell and anti-inflammatory markers rose.
Less amyloid. Amyloid-beta buildup and plaque load dropped, alongside higher levels of insulin-degrading enzyme, which helps clear amyloid.
A clear mechanism. Tβ4 dampened NF-κB signaling, a central switch for inflammation, through both of its main pathways.
Better memory. Treated mice did better on working-memory tests and showed less depression-like behavior.

Study 2: Human brain organoids point to the same protein (2025)

A 2025 study in Stem Cell Reports came at Tβ4 from the other direction. Researchers grew brain organoids, tiny three-dimensional clusters of brain tissue, from stem cells carrying mutations that cause inherited early-onset Alzheimer’s. Compared with healthy organoids, the Alzheimer’s organoids had more amyloid-beta, fewer mature neurons, and more dying cells.

When the team looked for genes that differed, the one encoding Tβ4 was markedly lower in the Alzheimer’s organoids’ neurons. Adding Tβ4 back reduced amyloid-beta and rescued neuron development, and the researchers reported similar rescue in a mouse model.

The appeal of this study is that it started with human cells and arrived at Tβ4 without looking for it.

What this does and doesn’t mean for TB-500

TB-500 isn’t the same molecule. It’s usually a short synthetic fragment of Tβ4, not the full 43-amino-acid protein used in this research. Whether the fragment does the same things in the brain hasn’t been shown.
Delivery is a big gap. The 2021 mice had Tβ4 produced inside their brains. Whether a peptide injected elsewhere in the body reaches the brain in useful amounts is a separate, unanswered question.
These are mouse and cell studies. Many approaches that cleared amyloid in mice have failed in people with Alzheimer’s.
Regulatory status: TB-500 isn’t an approved drug. It was one of the peptides an FDA advisory committee recommended for pharmacy compounding in July 2026, a recommendation that isn’t yet final. See our explainer on the 2026 FDA changes.

Bottom line

Two independent lines of research, one in mice and one in human-derived brain tissue, both link Tβ4 to less amyloid and healthier neurons. That makes Tβ4 a credible Alzheimer’s research target. It doesn’t yet make TB-500 an Alzheimer’s treatment.

Sources

Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice. Journal of Neuroinflammation. 2021. doi:10.1186/s12974-021-02166-3
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. Stem Cell Reports. 2025. PubMed 40816274